Jacob Johnson
Stock Analyst at Stephens & Co.
(2.87)
# 1,812
Out of 4,944 analysts
75
Total ratings
45.76%
Success rate
8.27%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $247.07 | -2.86% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $7.05 | -14.89% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $7.75 | -22.58% | 4 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $32.09 | +86.97% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $209.14 | +50.62% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $484.79 | +40.27% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $127.15 | +33.70% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $4.88 | +2.46% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $1.38 | +697.10% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $22.36 | +69.95% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $9.08 | +87.22% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.33 | +87.97% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $54.71 | +59.02% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $246.22 | +58.39% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $6.24 | +188.46% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $3.05 | +96.72% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $25.68 | +12.93% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $155.00 | +143.23% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $247.07
Upside: -2.86%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $7.05
Upside: -14.89%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $7.75
Upside: -22.58%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $32.09
Upside: +86.97%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $209.14
Upside: +50.62%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $484.79
Upside: +40.27%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $127.15
Upside: +33.70%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $4.88
Upside: +2.46%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.38
Upside: +697.10%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $22.36
Upside: +69.95%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $9.08
Upside: +87.22%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.33
Upside: +87.97%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $54.71
Upside: +59.02%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $246.22
Upside: +58.39%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $6.24
Upside: +188.46%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $3.05
Upside: +96.72%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $25.68
Upside: +12.93%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $155.00
Upside: +143.23%